- GBP/USD picks up bids towards the monthly high, prints seven-day winning streak.
- UK Times mark Whitehall source to cite Brexit deal, The Guardian quotes Chancellor Sunak to mark Britain’s tough stand.
- Pfizer will soon get the UK’s approval, Regeneron’s antibody treatment gets FDA’s green light.
- UK/US PMIs, Brexit headlines and virus/vaccine updates are the key.
GBP/USD refreshes intraday high to 1.3298 during the initial Asian session on Monday. The pair recently gained bids as the market turns optimistic concerning the Brexit deal and the coronavirus (COVID-19) vaccine. However, challenges to the Fed’s emergency programs and the rising virus figures in the northern hemisphere challenge the pair bulls.
Brexit deal not at any cost…
The UK Times cites an anonymous British government source to suggest that there are increasing expectations of a deal. The Sky follows the suit while citing the European Union’s (EU) side while indicating 95% chances of a Brexit deal. However, the piece also mentioned increased uncertainty over the key issues like fisheries, governance and competition rules that highlight the anxiety.
On the other hand, The Guardian quotes UK Finance Minister Rishi Sunak to probe the bulls while highlighting the British government’s readiness to step back from the deal if it’s not in their favor. The diplomat said, per the news, “We should not be going for a deal at any price, that would be the wrong thing to do and I think there are things that are important to us in these negotiations, and we’ve been entire, as I said, reasonable, consistent and transparent.”
Also on the negative side are the fears that the US Federal Reserve (Fed) will soon have to hand over $500 billion of emergency program funds to Treasury Secretary Steve Mnuchin.
Elsewhere, virus treatments are battling the risk-off mood. The Telegraph came out with the news suggesting that Pfizer will soon get approval from the UK government for its COVID-19 vaccine whereas Regeneron’s antibody treatment gets a go from the US Food and Drug Administration (FDA). It should also be noted that chatters surrounding a gradual easing of the covid-led activity restrictions also favor the GBP/USD bulls off-late.
Against this backdrop, S&P 500 Futures mark 0.10% intraday loss by press time.
Moving on, GBP/USD traders will pay close attention to the preliminary readings of November month PMI data for fresh impetus. Though, this doesn’t dim the importance of virus, vaccine and Brexit updates.
A clear break above the monthly high near 1.3315 becomes necessary for the bulls before challenging the yearly top of 1.3482. Meanwhile, a 10-day SMA near 1.3240 offers immediate support to watch during the quote’s pullback moves.
Additional important levels
|Today last price||1.3298|
|Today Daily Change||5 pips|
|Today Daily Change %||0.04%|
|Today daily open||1.3293|
|Previous Daily High||1.3298|
|Previous Daily Low||1.3247|
|Previous Weekly High||1.3312|
|Previous Weekly Low||1.3166|
|Previous Monthly High||1.3177|
|Previous Monthly Low||1.282|
|Daily Fibonacci 38.2%||1.3278|
|Daily Fibonacci 61.8%||1.3266|
|Daily Pivot Point S1||1.3261|
|Daily Pivot Point S2||1.3228|
|Daily Pivot Point S3||1.321|
|Daily Pivot Point R1||1.3312|
|Daily Pivot Point R2||1.333|
|Daily Pivot Point R3||1.3362|
Information on these pages contains forward-looking statements that involve risks and uncertainties. Markets and instruments profiled on this page are for informational purposes only and should not in any way come across as a recommendation to buy or sell in these assets. You should do your own thorough research before making any investment decisions. FXStreet does not in any way guarantee that this information is free from mistakes, errors, or material misstatements. It also does not guarantee that this information is of a timely nature. Investing in Open Markets involves a great deal of risk, including the loss of all or a portion of your investment, as well as emotional distress. All risks, losses and costs associated with investing, including total loss of principal, are your responsibility. The views and opinions expressed in this article are those of the authors and do not necessarily reflect the official policy or position of FXStreet nor its advertisers. The author will not be held responsible for information that is found at the end of links posted on this page.
If not otherwise explicitly mentioned in the body of the article, at the time of writing, the author has no position in any stock mentioned in this article and no business relationship with any company mentioned. The author has not received compensation for writing this article, other than from FXStreet.
FXStreet and the author do not provide personalized recommendations. The author makes no representations as to the accuracy, completeness, or suitability of this information. FXStreet and the author will not be liable for any errors, omissions or any losses, injuries or damages arising from this information and its display or use. Errors and omissions excepted.
The author and FXStreet are not registered investment advisors and nothing in this article is intended to be investment advice.